Literature DB >> 22138402

Frizzled-8 as a putative therapeutic target in human lung cancer.

Hua-qing Wang1, Mei-lin Xu, Jie Ma, Yi Zhang, Cong-hua Xie.   

Abstract

Lung cancer is the leading cause of cancer related deaths worldwide. It is necessary to better understand the molecular mechanisms involved in lung cancer in order to develop more effective therapeutics for the treatment of this disease. Recent reports have shown that Wnt signaling pathway is important in a number of cancer types including lung cancer. However, the role of Frizzled-8 (Fzd-8), one of the Frizzled family of receptors for the Wnt ligands, in lung cancer still remains to be elucidated. Here in this study we showed that Fzd-8 was over-expressed in human lung cancer tissue samples and cell lines. To investigate the functional importance of the Fzd-8 over-expression in lung cancer, we used shRNA to knock down Fzd-8 mRNA in lung cancer cells expressing the gene. We observed that Fzd-8 shRNA inhibited cell proliferation along with decreased activity of Wnt pathway in vitro, and also significantly suppressed A549 xenograft model in vivo (p<0.05). Furthermore, we found that knocking down Fzd-8 by shRNA sensitized the lung cancer cells to chemotherapy Taxotere. These data suggest that Fzd-8 is a putative therapeutic target for human lung cancer and over-expression of Fzd-8 may be important for aberrant Wnt activation in lung cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138402     DOI: 10.1016/j.bbrc.2011.11.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.

Authors:  Tsuyoshi Saito; Hiroyuki Mitomi; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway.

Authors:  Fukun Chen; Zhiping Feng; Jialun Zhu; Pengjie Liu; Chuanzhou Yang; Rongkai Huang; Zhiyong Deng
Journal:  Cancer Biol Ther       Date:  2018-09-12       Impact factor: 4.742

3.  GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adenocarcinoma.

Authors:  S Yuan; Z Yu; Q Liu; M Zhang; Y Xiang; N Wu; L Wu; Z Hu; B Xu; T Cai; X Ma; Y Zhang; C Liao; L Wang; P Yang; L Bai; Y Li
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

4.  Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.

Authors:  Shuping Yin; Liping Xu; R Daniel Bonfil; Sanjeev Banerjee; Fazlul H Sarkar; Seema Sethi; Kaladhar B Reddy
Journal:  Mol Cancer Ther       Date:  2013-02-27       Impact factor: 6.261

Review 5.  Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

Authors:  Phuong N Le; Jessica D McDermott; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

Review 6.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer.

Authors:  Koji Ueno; Hiroshi Hirata; Yuji Hinoda; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

7.  CDX2 is an amplified lineage-survival oncogene in colorectal cancer.

Authors:  Keyan Salari; Mary E Spulak; Justin Cuff; Andrew D Forster; Craig P Giacomini; Stephanie Huang; Melissa E Ko; Albert Y Lin; Matt van de Rijn; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

8.  MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway.

Authors:  Qian Jiang; Miao He; Shu Guan; Mengtao Ma; Huizhe Wu; Zhaojin Yu; Longyang Jiang; Yan Wang; Xingyue Zong; Feng Jin; Minjie Wei
Journal:  Tumour Biol       Date:  2015-11-04

9.  An ensemble prognostic model for colorectal cancer.

Authors:  Bi-Qing Li; Tao Huang; Jian Zhang; Ning Zhang; Guo-Hua Huang; Lei Liu; Yu-Dong Cai
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

10.  Expression and prognostic impact of FZDs in pancreatic adenocarcinoma.

Authors:  Yang Li; Zirong Liu; Yamin Zhang
Journal:  BMC Gastroenterol       Date:  2021-02-22       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.